You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Article info

Article menu

Download PDFPDF

XML
Pharmacology and therapeutics
Protocol
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial

Authors

  • Anastasia Suraev Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaThe University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, AustraliaThe University of Sydney, Brain and Mind Centre, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ronald R Grunstein Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaRPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Nathaniel S Marshall Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Medicine and Health, Susan Wakil School of Nursing and Midwifery, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Angela L D'Rozario Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Christopher J Gordon Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Medicine and Health, Susan Wakil School of Nursing and Midwifery, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Delwyn J Bartlett Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Keith Wong Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaRPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Brendon J Yee Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaRPA-Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Ryan Vandrey Behavioral Pharmacology Research Unit, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Chris Irwin Menzies Health Institute Queensland, School Allied Health Sciences, Griffith University, Gold Coast, Queensland, Australia PubMed articlesGoogle scholar articles
  • Jonathon C Arnold The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Sydney, New South Wales, AustraliaThe University of Sydney, Brain and Mind Centre, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Medicine and Health, Discipline of Pharmacology, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Iain S McGregor The University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, AustraliaThe University of Sydney, Brain and Mind Centre, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Camilla M Hoyos Woolcock Institute of Medical Research, Centre for Sleep and Chronobiology, Sydney, New South Wales, AustraliaThe University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, AustraliaThe University of Sydney, Brain and Mind Centre, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Camilla M Hoyos; camilla.hoyos{at}sydney.edu.au
View Full Text

Citation

Suraev A, Grunstein RR, Marshall NS, et al
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder (‘CANSLEEP’ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial
BMJ Open 2020;10:e034421. doi: 10.1136/bmjopen-2019-034421

Publication history

  • Received September 19, 2019
  • Revised January 6, 2020
  • Accepted March 11, 2020
  • First published May 18, 2020.
Online issue publication 
May 18, 2020
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.